Experience with tofacitinib in the treatment of resistant rheumatoid arthritis

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis

The Russian Federation has not got sufficient experience with tofacitinib (TOFA) in patients with rheumatoid arthritis (RA) so far; in this connection, all follow-ups using this drug in real clinical practice are of particular interest.Objective: to evaluate the efficancy and safety of TOFA in an op...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. R. Babaeva, E. V. Kalinina, D. E. Karateev
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2015-06-01
Series:	Современная ревматология
Subjects:	rheumatoid arthritis biological agents jak-kinase inhibitors tofacitinib
Online Access:	https://mrj.ima-press.net/mrj/article/view/619
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The marked and rapid therapeutic effect of tofacitinib in combination with subcutaneous methotrexate in a rheumatoid arthritis patient with poor prognostic factors who is resistant to standard disease-modifying antirheumatic drugs and biologicals: A clinical case
by: N. V. Demidova, et al.
Published: (2016-03-01)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01)

Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis
by: I. V. Menshikova, et al.
Published: (2019-05-01)

Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)
by: E. L. Nasonov, et al.
Published: (2020-02-01)

THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS
by: V. I. Mazurov, et al.
Published: (2018-05-01)

Clinical significance of Janus kinase inhibitors in the therapy of rheumatoid arthritis: achievements and prospects
by: V. I. Mazurov, et al.
Published: (2019-10-01)

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE
by: E. Yu. Loginova, et al.
Published: (2020-06-01)

Tofacitinib as an adjuvant treatment for pediatric Still's disease
by: Ling Hou, et al.
Published: (2025-08-01)

Efficacy and safety of Tofacitinib in patients with active rheumatoid arthritis resistant to conventional therapy: Preliminary results of an open-label clinical trial
by: E. L. Luchikhina, et al.
Published: (2016-06-01)

Letter to the Editor Regarding the Article "Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials"
by: YanRan Qiu, et al.
Published: (2025-03-01)

The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2017-03-01)

Effective Treatment of Livedoid Vasculopathy With Oral Tofacitinib
by: Parvin Mansouri, et al.
Published: (2025-06-01)

A Case Series Report on the Effect of Tofacitinib on Joint Inflammation and Gut Microbiota Composition in Psoriatic Arthritis Patients Naive to Biologic Agents
by: Andrea Picchianti Diamanti, et al.
Published: (2024-11-01)

Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report
by: Yijia He, et al.
Published: (2025-04-01)

A new trend in pathogenetic treatment of rheumatoid arthritis: tofacitinib, the first inhibitor of Janus kinase
by: Dmitry Evgenyevich Karateev
Published: (2014-03-01)

A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements
by: A. E. Karateev, et al.
Published: (2020-05-01)

Retention on tofacitinib therapy in patients with rheumatoid arthritis (real clinical practice data)
by: G. I. Gridneva, et al.
Published: (2022-12-01)

Management of Generalized Vitiligo in Adolescent with Tofacitinib: Clinical Case
by: Eduard T. Ambarchyan, et al.
Published: (2024-11-01)

Ultrasound Evaluation of Therapeutic Response to Tofacitinib and Upadacitinib in Patients with Rheumatoid Arthritis—Real-Life Clinical Data
by: Vladimira Boyadzhieva, et al.
Published: (2025-05-01)

Circulating exo-miRNA-27a-5p is a novel biomarker of the tofacitinib treatment response in rheumatoid arthritis
by: Jiwei Zhao, et al.
Published: (2025-04-01)

Comparative effectiveness and safety of tofacitinib vs. adalimumab in patients with rheumatoid arthritis: A systematic review and meta-analysis
by: Chunyan Zhu, et al.
Published: (2025-06-01)

Effects of Tofacitinib Therapy on Circulating Tumour-Associated Antigens and Their Relationship with Clinical, Laboratory and Vascular Parameters in Rheumatoid Arthritis
by: Enikő Sebestyén, et al.
Published: (2025-04-01)

Evaluation of the effectiveness of Tofacitinib in rheumatoid arthritis in real clinical practice: The relationship between pain relief in the first 4 weeks and disease activity after 3–6 months
by: A. E. Karateev, et al.
Published: (2021-09-01)

Research progress on tofacitinib in the treatment of chronic actinic dermatitis
by: WU Hui, et al.
Published: (2024-12-01)

The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases
by: E. L. Nasonov, et al.
Published: (2020-11-01)

Evolving strategies in the treatment of rheumatoid arthritis: a historical perspective
by: Julia Domańska-Poboża, et al.
Published: (2025-02-01)

The efficacy of narrowband ultraviolet B phototherapy combination with tofacitinib in the treatment of vitiligo: a randomized controlled trial
by: Xiaoyan Guo, et al.
Published: (2025-12-01)

Chronic pain and central sensitization in immuno-inflammatory rheumatic diseases: pathogenesis, clinical manifestations, the possibility of using targeted disease modifying antirheumatic drugs
by: A. E. Karateev, et al.
Published: (2019-05-01)

EFFICACY AND SAFETY OF TOFACITINIB FOR IMMUNEMEDIATED INFLAMMATORY RHEUMATIC DISEASES (PART II)
by: E. L. Nasonov, et al.
Published: (2020-04-01)

Association between a low baseline level of gene expression of energy metabolism in the blood and the development of clinical remission in response to tofacitinib therapy in patients with rheumatoid arthritis
by: E. V. Chetina, et al.
Published: (2021-06-01)

The use of methotrexate in rheumatoid arthritis. Recommendations of the All-Russian public organization “Association of Rheumatologists of Russia”
by: E. L. Nasonov, et al.
Published: (2023-08-01)

Successful treatment of a case of dupilumab-induced psoriasis and alopecia areata with tofacitinib
by: SUN Feifei, et al.
Published: (2025-06-01)

Tofacitinib treatment for psoriatic skin lesions associated with Aicardi-Goutières syndrome 7/Singleton-Merten syndrome 1
by: Shanice Beerepoot, et al.
Published: (2025-04-01)

Central sensitization reduces the satisfaction of patients with rheumatoid arthritis. The data of prospective study
by: A. S. Potapova, et al.
Published: (2024-11-01)

ANALYSIS OF THE RESULTS OF TOFACITINIB THERAPY IN REAL CLINICAL PRACTICE ACCORDING TO THE ALL-RUSSIAN ARTHRITIS REGISTRY (OREL)
by: A. S. Avdeeva, et al.
Published: (2020-06-01)

Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients
by: E. E. Gubar, et al.
Published: (2021-05-01)

Nocturnal baricitinib administration leads to rapid drug responses in rheumatoid arthritis: a multicenter non-randomized controlled study
by: Teppei Hashimoto, et al.
Published: (2025-04-01)

Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib
by: A. E. Karateev
Published: (2020-09-01)

Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2016-09-01)

Treatment strategy for rheumatoid arthritis: hot topics
by: D. E. Karateev
Published: (2015-03-01)